Therapeutic Antibodies

#Biologics #Drug development #Drug discovery #Immuno-oncology #Monoclonal antibodies

The potential of small molecules and biologics for new therapeutics 

Listen to this article on the DDW Podcast: Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. He talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.  Since its formation in 2011, Tonix Pharmaceuticals… Read More

#Business & Investment #Exclusive Content #News

#Biologics #Drug development #Flow Cytometry #Immunogenicity #Therapeutics

Cellular assays to bridge the gap in immunogenicity prediction 

Listen to this article on the DDW Podcast: Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development.  Biologic drugs as therapy have improved the treatment of many diseases, but their success is… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Antibodies #Antibody libraries #Biologics #Biopharmaceuticals #DNA #Drug discovery #Drug targets #Screening

Newly launched antibody libraries put hard-to-drug targets within reach

Target class-specific libraries mean you need to screen less to identify high-quality antibodies. Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates. Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics. However, only a few general-purpose libraries have been commercially available for drug discovery. As a result,… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Antibodies #Collaboration #Drug development #Drug discovery #Monoclonal antibodies

Nautilus and Abcam partner to accelerate proteome exploration  

Nautilus Biotechnology and Abcam have announced a strategic development and supply partnership to leverage Abcam’s recombinant monoclonal antibody development technologies and expertise to enhance Nautilus’ reagent research and development.   The partnership will initially focus on the collaborative development of affinity binding reagents for use on the… Read More

#News #Trending News

#Antivirals #Biologics #Biopharmaceuticals #Collaboration #Covid-19 #Laboratory data

This week in drug discovery (1-5 November) 

News round-up by DDW’s Megan Thomas for 1-5 November DDW’s Megan Thomas has selected five stories which showcase the international scope of the drug discovery industry in terms of research, innovation, collaboration and development. 1. New consortium to boost Covid-19 vaccine production in South Africa The Medicines Patent… Read More

#News #Trending News

#Biologics #Cell and gene therapy #Cobra Biologics #DNA

Swedish government and industry to boost product partnerships 

Flerie Invest led a syndicate of investors in the $52 million acquisition of Cobra Biologics, Charles River Laboratories’ DNA and protein manufacturing subsidiary in Sweden. The new entity, NorthX Biologics, will take over and expand the facility, which is equipped to provide GMP-grade plasmid DNA and technical protein manufacture at commercial scale. … Read More

#News #Trending News #Trends & Analysis

#Antibodies #Biotherapeutics #Therapeutics

New platform could improve potency and efficacy of therapeutic antibodies 

PerkinElmer is expanding its Horizon Discovery CHOSOURCE platform to include a new expression cell line, CHO-K1 ADCC+, which may improve potency and efficacy of therapeutic antibodies and fusion protein biotherapeutics, as well as reduce dosage requirements and side effects for patients.   This new expression host was built… Read More

#News

#Antibodies #Covid-19 #Drug development #Drug discovery #Preclinical development #Therapeutics

Highlights of Carterra’s Bamlanivimab story

A recent sponsored DDW Sitting Down With podcast covered the bamlanivimab story and how this therapeutic went from lab to clinic in eight months during the pandemic. It is available to listen to here. Lu Rahman selects some of the highlights of this chat with Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli… Read More

#Covid-19 #Exclusive Content #News

#Antibodies #Bispecific therapeutics #Drug development #Drug discovery

Approaching bispecific antibody engineering

Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project  who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Trends & Analysis

#Antibodies #Covid-19 #Drug discovery #Drug therapy #Infographic #Monoclonal antibodies #Research

Study illuminates surfaces of spike most resistant to antibody escape 

Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, which was generated by a global collaboration comparing nearly all leading clinical candidates. The new research, published in Science, will guide the development of more effective Covid-19 antibody… Read More

#Covid-19 #News

#Antibodies #Clinical trials #Data #Monoclonal antibodies

AstraZeneca Imfinzi combination effective with non-small cell lung cancer 

Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had… Read More

#News

#Biologics #Drug discovery #Drug therapy #Events #Immunotherapy

Two-day biologics drug discovery course open for registration 

Join Terrence Kenakin as he presents a two-day Applied course on September 21 and September 22 at 10AM CDT.   This two-day course will introduce the topic of biologics as a drug therapy in addition to recombinant replacement protein biologics, peptide signalling, immunotherapy, antibodies features, and nucleotide-based… Read More

#News

#Antibodies #Biotherapeutics #Collaboration #Drug discovery

Collaboration to support preclinical drug discovery research 

Fusion Antibodies has entered into a commercial collaboration with Eurofins to provide laboratories worldwide with high-quality, cost-effective and efficient services that work with one another to support biotherapeutic discovery.   Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to… Read More

#Business & Investment #News

#Biologics #Cannabinoid #Cell programming

Partnership achieves equity milestone to produce cannabinoids 

Cronos Group and Ginkgo Bioworks have achieved the first target productivity milestone in their partnership to produce eight cultured cannabinoids.   Using Ginkgo’s platform for organism design and development, Cronos Group has successfully achieved the productivity target for cannabigerolic acid (CBGA), which will support Cronos Group’s planned CBG product launch this fall. … Read More

#News